Pfizer says that patent expiries are only one reason why it is cutting manufacturing. Its purchase of rival Wyeth last year created redundancies and new options for creating efficiency. It will need to. Exactly how much cost drug companies can wring out of their balance sheets as patents expire is one of the key questions facing the pharmaceutical industry as they head over what analysts are calling the patent cliff.